LCN2 and breast carcinoma: We further validated these findings by analyzing a meta‐dataset of 8951 breast cancers, in which 87% of tumor samples were classified as LCN2‐low (n = 7830/8951) and 13% as LCN2‐high (n = 1121/8951).